The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2017 | Factors to consider when choosing treatment for relapsed multiple myeloma patients
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses how to choose treatment for a patient with relapsed multiple myeloma (MM) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. It is important to consider the individual patient’s perspective and what treatment they would like to have as well as their co-morbidities. Further, you need to look at their disease, including their kidney function and genetic alterations. Finally, it is important to go through their treatment history in case they might have resistances.
